Published in Cancer Gene Ther on May 01, 2005
Tissue- and tumor-specific targeting of murine leukemia virus-based replication-competent retroviral vectors. J Virol (2006) 0.88
Influence of vector design and host cell on the mechanism of recombination and emergence of mutant subpopulations of replicating retroviral vectors. BMC Mol Biol (2009) 0.78
APOBEC3 proteins inhibit human LINE-1 retrotransposition. J Biol Chem (2006) 3.30
Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature (2011) 2.94
Targeted cell entry of lentiviral vectors. Mol Ther (2008) 2.34
Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem (2004) 2.33
The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc Natl Acad Sci U S A (2005) 1.95
Functions, structure, and read-through alternative splicing of feline APOBEC3 genes. Genome Biol (2008) 1.63
T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing. Blood (2012) 1.55
Specific gene delivery to liver sinusoidal and artery endothelial cells. Blood (2013) 1.51
Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods (2010) 1.48
Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nat Biotechnol (2002) 1.48
CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors. Mol Ther Nucleic Acids (2013) 1.45
European regulation tackles tissue engineering. Nat Biotechnol (2007) 1.42
Multivalent antibodies: when design surpasses evolution. Trends Biotechnol (2010) 1.28
The large-scale digital cell analysis system: an open system for nonperturbing live cell imaging. J Microsc (2007) 1.27
Lipopolysaccharide activates Toll-like receptor 4 (TLR4)-mediated NF-κB signaling pathway and proinflammatory response in human pericytes. J Biol Chem (2013) 1.23
Lentiviral vectors with measles virus glycoproteins - dream team for gene transfer? Trends Biotechnol (2009) 1.18
Stathmin and interfacial microtubule inhibitors recognize a naturally curved conformation of tubulin dimers. J Biol Chem (2010) 1.15
Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol (2002) 1.14
Antibody engineering: facing new challenges in cancer therapy. Acta Pharmacol Sin (2005) 1.14
Species-specific inhibition of APOBEC3C by the prototype foamy virus protein bet. J Biol Chem (2008) 1.12
Interaction of Vpx and apolipoprotein B mRNA-editing catalytic polypeptide 3 family member A (APOBEC3A) correlates with efficient lentivirus infection of monocytes. J Biol Chem (2010) 1.12
Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res (2006) 1.12
Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds. Stem Cells (2009) 1.09
DARPins: an efficient targeting domain for lentiviral vectors. Mol Ther (2011) 1.08
Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. Cancer Res (2013) 1.05
Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events. Hum Gene Ther (2010) 1.04
In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences. PLoS One (2009) 1.02
Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Res (2007) 1.02
Lentiviral vectors targeted to MHC II are effective in immunization. Hum Gene Ther (2011) 1.02
Multiple restrictions of human immunodeficiency virus type 1 in feline cells. J Virol (2007) 1.00
Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery? Hum Gene Ther (2002) 1.00
Antibodies and gene therapy: teaching old 'magic bullets' new tricks. Trends Immunol (2004) 0.99
Restriction of measles virus RNA synthesis by a mouse host cell line: trans-complementation by polymerase components or a human cellular factor(s). J Virol (2002) 0.98
Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases. J Virol (2009) 0.98
Sp1 and Sp3 regulate basal transcription of the human APOBEC3G gene. Nucleic Acids Res (2007) 0.97
Impact of viral accessory proteins of SIVsmmPBj on early steps of infection of quiescent cells. Virology (2007) 0.97
Selection of functional human antibodies from retroviral display libraries. Nucleic Acids Res (2005) 0.97
The proline-rich region of the ecotropic Moloney murine leukaemia virus envelope protein tolerates the insertion of the green fluorescent protein and allows the generation of replication-competent virus. J Gen Virol (2003) 0.97
Restriction of HIV-1 replication in monocytes is abolished by Vpx of SIVsmmPBj. PLoS One (2009) 0.96
Identification and activity of a series of azole-based compounds with lactate dehydrogenase-directed anti-malarial activity. J Biol Chem (2004) 0.96
A novel cell binding site in the coiled-coil domain of laminin involved in capillary morphogenesis. EMBO J (2003) 0.94
Model structure of APOBEC3C reveals a binding pocket modulating ribonucleic acid interaction required for encapsidation. Proc Natl Acad Sci U S A (2009) 0.94
The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies. J Biol Chem (2010) 0.94
Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. J Immunol (2003) 0.94
Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP. J Virol (2005) 0.94
Identification of R-peptides in envelope proteins of C-type retroviruses. J Gen Virol (2002) 0.93
Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events. Int J Cancer (2006) 0.92
Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol Ther (2012) 0.92
Generation and characterization of monospecific and bispecific hexavalent trimerbodies. MAbs (2012) 0.91
Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth. Cancer Gene Ther (2005) 0.91
Functional improvement of antibody fragments using a novel phage coat protein III fusion system. Biochem Biophys Res Commun (2002) 0.90
Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies. Proc Natl Acad Sci U S A (2013) 0.90
A global regulatory science agenda for vaccines. Vaccine (2013) 0.89
Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. Int J Cancer (2002) 0.89
Targeted retroviral vectors displaying a cleavage site-engineered hemagglutinin (HA) through HA-protease interactions. Mol Ther (2006) 0.89
DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety. Mol Ther (2013) 0.88
Stable transduction of primary human monocytes by simian lentiviral vector PBj. Mol Ther (2005) 0.88
Lymphocyte display: a novel antibody selection platform based on T cell activation. PLoS One (2009) 0.88
Manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective. J Immunother (2006) 0.87
Development of a computer-assisted high-throughput screening platform for anti-angiogenic testing. Microvasc Res (2002) 0.86
Microencapsulation of therapeutic bispecific antibodies producing cells: immunotherapeutic organoids for cancer management. J Drug Target (2014) 0.86
Vesicular stomatitis virus glycoprotein displaying retrovirus-like particles induce a type I IFN receptor-dependent switch to neutralizing IgG antibodies. J Immunol (2007) 0.86
The kinase insert domain-containing receptor is an angiogenesis-associated antigen recognized by human cytotoxic T lymphocytes. Blood (2005) 0.86
Comparative analysis of transduced primary human dendritic cells generated by the use of three different lentiviral vector systems. Mol Biotechnol (2011) 0.85
The heterotrimeric laminin coiled-coil domain exerts anti-adhesive effects and induces a pro-invasive phenotype. PLoS One (2012) 0.85
Directed evolution of retrovirus envelope protein cytoplasmic tails guided by functional incorporation into lentivirus particles. J Virol (2005) 0.85
The US and EU regulatory perspectives on the clinical use of hematopoietic stem/progenitor cells genetically modified ex vivo by retroviral vectors. Methods Mol Biol (2009) 0.85
Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice. J Immunol (2009) 0.85
Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies. PLoS One (2012) 0.85
Bacterial tubulin distinct loop sequences and primitive assembly properties support its origin from a eukaryotic tubulin ancestor. J Biol Chem (2011) 0.84
Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. Oncoimmunology (2012) 0.83
Genetic engineering of onco/lentivirus hybrids results in formation of infectious but not of replication-competent viruses. J Gen Virol (2004) 0.83
Prototype foamy virus Bet impairs the dimerization and cytosolic solubility of human APOBEC3G. J Virol (2013) 0.83
Engineering human cells for in vivo secretion of antibody and non-antibody therapeutic proteins. Curr Opin Biotechnol (2011) 0.83
Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. Med Oncol (2013) 0.83
The therapeutic potential of engineered human neovessels for cell-based gene therapy. Expert Opin Biol Ther (2010) 0.83
Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. Biochem J (2005) 0.83
Three-Color FRET expands the ability to quantify the interactions of several proteins involved in actin filament nucleation. Proc SPIE Int Soc Opt Eng (2012) 0.82
Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus. Cancer Res (2010) 0.82
Human CD4+ T lymphocytes recognize a vascular endothelial growth factor receptor-2-derived epitope in association with HLA-DR. Clin Cancer Res (2008) 0.82
Antibody engineering, virus retargeting and cellular immunotherapy: one ring to rule them all? Curr Gene Ther (2005) 0.82
The receptor attachment function of measles virus hemagglutinin can be replaced with an autonomous protein that binds Her2/neu while maintaining its fusion-helper function. J Virol (2013) 0.82